Skip to main content

Adjuvant Therapy of Gallbladder Cancer

  • Chapter
  • First Online:
Gallbladder Cancer

Abstract

Gallbladder cancer is a rare gastrointestinal malignancy having a poor prognosis because of its late presentation of disease, early invasion, and lack of effective systemic therapy. Surgical extirpation with negative margins remains the only chance for cure in patients with gallbladder cancer. Despite the best attempts at curative resection, a majority of patients with GBC usually recur. Therefore, effective adjuvant therapies are needed to decrease disease recurrence and to improve survival. Recurrence following surgery is a major barrier to providing long-term survival in patients with GBC. The use of adjuvant therapy has been found to be effective through various clinical trials. In the present chapter, we have discussed the data on adjuvant treatment of GBC and explore therapeutic methods for the patients in the adjuvant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

    Article  Google Scholar 

  2. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689–700.

    Article  Google Scholar 

  3. Gamboa AC, Maithel SK. The landmark series: gallbladder cancer. Ann Surg Oncol. 2020;27(8):2846–58.

    Article  Google Scholar 

  4. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–27.

    Article  Google Scholar 

  5. Boutros C, Gary M, Baldwin K, Somasundar P. Gallbladder cancer: past, present and an uncertain future. Surg Oncol. 2012;21(4):e183–91.

    Article  CAS  Google Scholar 

  6. Dixon E, Vollmer CM Jr, Sahajpal A, et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a north American center. Ann Surg. 2005;241(3):385–94.

    Article  Google Scholar 

  7. Lee SE, Jang JY, Lim CS, Kang MJ, Kim SW. Systematic review on the surgical treatment for T1 gallbladder cancer. World J Gastroenterol. 2011;17(2):174–80.

    Article  Google Scholar 

  8. Fuks D, Regimbeau JM, Le Treut YP, et al. Incidental gallbladder cancer by the AFC-GBC-2009 study group. World J Surg. 2011;35(8):1887–97.

    Article  Google Scholar 

  9. D'Angelica M, Dalal KM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16(4):806–16.

    Article  Google Scholar 

  10. Hueman MT, Vollmer CM Jr, Pawlik TM. Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol. 2009;16(8):2101–15.

    Article  Google Scholar 

  11. Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg. 1996;224(5):639–46.

    Article  CAS  Google Scholar 

  12. Kim TG. Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy. Radiat Oncol J. 2017;35(4):359–67.

    Article  Google Scholar 

  13. Network NCC. Hepatobiliary cancers (Version 2.2021). 2021; https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed 13 May 2021

  14. Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: to treat or not to treat? World J Gastroenterol. 2012;18(21):2591–6.

    Article  Google Scholar 

  15. Mallick S, Benson R, Haresh KP, Julka PK, Rath GK. Adjuvant radiotherapy in the treatment of gall bladder carcinoma: what is the current evidence. J Egypt Natl Canc Inst. 2016;28(1):1–6.

    Article  Google Scholar 

  16. Glazer ES, Liu P, Abdalla EK, Vauthey JN, Curley SA. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg. 2012;16(9):1666–71.

    Article  Google Scholar 

  17. Tran Cao HS, Zhang Q, Sada YH, Chai C, Curley SA, Massarweh NN. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Cancer. 2018;124(1):74–83.

    Article  Google Scholar 

  18. Ma N, Cheng H, Qin B, Zhong R, Wang B. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer. 2015;15:615.

    Article  Google Scholar 

  19. Cho SY, Kim SH, Park SJ, et al. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol. 2010;102(1):87–93.

    Article  Google Scholar 

  20. Kim Y, Amini N, Wilson A, et al. Impact of chemotherapy and external-beam radiation therapy on outcomes among patients with resected gallbladder cancer: a multi-institutional analysis. Ann Surg Oncol. 2016;23(9):2998–3008.

    Article  Google Scholar 

  21. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.

    Article  Google Scholar 

  22. Mantripragada KC, Hamid F, Shafqat H, Olszewski AJ. Adjuvant therapy for resected gallbladder cancer: analysis of the National Cancer Data Base. J Natl Cancer Inst. 2017;109(2):djw202.

    Article  Google Scholar 

  23. Hoehn RS, Wima K, Ertel AE, et al. Adjuvant therapy for gallbladder cancer: an analysis of the National Cancer Data Base. J Gastrointest Surg. 2015;19(10):1794–801.

    Article  Google Scholar 

  24. Ghidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB (Oxford). 2017;19(9):741–8.

    Article  Google Scholar 

  25. Wang J, Narang AK, Sugar EA, et al. Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience. Ann Surg Oncol. 2015;22(Suppl 3):S1100–6.

    Article  Google Scholar 

  26. Bergquist JR, Shah HN, Habermann EB, et al. Adjuvant systemic therapy after resection of node positive gallbladder cancer: time for a well-designed trial? (results of a US-national retrospective cohort study). Int J Surg. 2018;52:171–9.

    Article  Google Scholar 

  27. Mitin T, Enestvedt CK, Jemal A, Sineshaw HM. Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival. J Natl Cancer Inst. 2017;109(7).

    Google Scholar 

  28. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–95.

    Article  Google Scholar 

  29. Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and Oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658–67.

    Article  CAS  Google Scholar 

  30. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.

    Article  CAS  Google Scholar 

  31. Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192–202.

    Article  CAS  Google Scholar 

  32. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

    Article  CAS  Google Scholar 

  33. André T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862–7.

    Article  Google Scholar 

  34. Takada T, Nimura Y, Katoh H, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology. 1998;45(24):2020–6.

    CAS  Google Scholar 

  35. Itano O, Takemura Y, Kishida N, et al. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo study Group for Biliary Cancer: TOSBIC01). BMC Cancer. 2020;20(1):688.

    Article  CAS  Google Scholar 

  36. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant Capecitabine and gemcitabine followed by radiotherapy and concurrent Capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617–22.

    Article  CAS  Google Scholar 

  37. Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016;35(2):263–75.

    Article  CAS  Google Scholar 

  38. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–9.

    Article  CAS  Google Scholar 

  39. Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019;10(4):652–62.

    Article  Google Scholar 

  40. Lamarca A, Edeline J, McNamara MG, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936.

    Article  CAS  Google Scholar 

  41. Okamura R, Kurzrock R, Mallory RJ, et al. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021;148(3):702–12.

    Article  CAS  Google Scholar 

  42. Golan T, Raitses-Gurevich M, Kelley RK, et al. Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study. Oncologist. 2017;22(7):804–10.

    Article  CAS  Google Scholar 

  43. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109–15.

    Article  CAS  Google Scholar 

  44. Xie Y, Jiang Y, Yang XB, et al. Response of BRCA1-mutated gallbladder cancer to olaparib: a case report. World J Gastroenterol. 2016;22(46):10254–9.

    Article  Google Scholar 

  45. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069–74.

    Article  CAS  Google Scholar 

  46. Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study. J Clin Oncol. 2010;28(21):3491–7.

    Article  CAS  Google Scholar 

  47. Kim ST, Jang KT, Lee SJ, et al. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer. 2015;15:530.

    Article  Google Scholar 

  48. El-Khoueiry AB, Rankin C, Siegel AB, et al. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014;110(4):882–7.

    Article  CAS  Google Scholar 

  49. Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol. 2016;7(5):797–803.

    Article  Google Scholar 

  50. Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58.

    Article  Google Scholar 

  51. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY). 2017;357(6349):409–13.

    Article  CAS  Google Scholar 

  52. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

    Article  CAS  Google Scholar 

  53. Ross JS, Wang K, Javle MM, et al. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. J Clin Oncol. 2015;33(15_suppl):4009.

    Article  Google Scholar 

  54. Neyaz A, Husain N, Kumari S, et al. Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy. Histopathology. 2018;73(4):622–33.

    Article  Google Scholar 

  55. Lin J, Long J, Wan X, et al. Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression. BMC Cancer. 2018;18(1):766.

    Article  Google Scholar 

  56. Bezu L, Gomes-de-Silva LC, Dewitte H, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.

    Google Scholar 

  57. Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190–8.

    Article  CAS  Google Scholar 

  58. Fujiwara Y, Koyama T, Helwig C, Watanabe M, Doi T. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with advanced solid tumors. J Clin Oncol. 2018;36(4_suppl):762.

    Article  Google Scholar 

  59. Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of Nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888–94.

    Article  Google Scholar 

  60. Montalvo-Jave EE, Rahnemai-Azar AA, Papaconstantinou D, et al. Molecular pathways and potential biomarkers in gallbladder cancer: a comprehensive review. Surg Oncol. 2019;31:83–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Timothy M. Pawlik .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Brown, Z.J., Hewitt, D.B., Pawlik, T.M. (2023). Adjuvant Therapy of Gallbladder Cancer. In: Kumar Shukla, V., Pandey, M., Dixit, R. (eds) Gallbladder Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-19-6442-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-6442-8_4

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-6441-1

  • Online ISBN: 978-981-19-6442-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics